第二型糖尿病(type 2 diabetes mellitus，T2DM)是一個致病機轉複雜的内分泌代謝疾病，因其迅速增 加的盛行率及所導致的多重併發症，對患者和社會而言都是一項巨大的負擔，所以更是全球所關心的主 要公共健康問題。目前雖已有多種抗糖尿病藥物可選擇，T2DM患者長期良好的血糖控制仍是備受挑戰。 腎臟透過腎小球再吸收葡萄糖來調節血糖的恆定，新一類的降血糖藥-鈉-葡萄糖共同輸送器-2抑制劑 (sodium-glucose cotransporter2inhibitors，SGLT-2 inhibitors)，藉由抑制腎臟再吸收葡萄糖，提供了一個與 胰島素獨立無關的作用機轉，本文將討論其效果和安全性，期望能提供臨床醫療人員更多的資訊，選擇對病人最有利的方式，以達到良好的血糖控制目標。

Type 2 diabetes mellitus (T2DM) is a complex endocrine and metabolic disease. Because of the rapid increasing prevalence of T2DM and its multiple complications, it became a major threat to public health. Although a variety of anti-diabetic drugs is now available, the long-term glycemic control of T2DM remains challenging. The kidneys contribute significantly to glucose homeostasis by reabsorbing glucose from the glomerular filtrate. Sodium-glucose cotransporter 2 (SGLT2) inhibitors, a new class of antidiabetic agents that inhibit glucose absorption from the kidney independent of insulin, offer a unique opportunity to improve the outcomes of patients with T2DM. This article will discuss the efficacy and safety of SGLT2 inhibitors with the hope to provide more information for clinical medical staffs to select the optimal way for patients to achieve the goal of glycemic control.